

REMARKS

The specification has been amended with respect to the continuity data. Specifically, application 09/964,025 has been allowed as United States Patent No. 6,686,347 and such is now indicated.


Claims 1-5, 19, 21, 22, 29, 31 and 32 have been rejected under 35 U.S.C. § 101 and § 112, first paragraph. Claims 5, 19, 21, 22 have been cancelled. Claims 1-4, 29, 31 and 32 have been amended to recite method of treatment claims to conform to proper US claim practice. Applicants respectfully submit that these amendments overcome the rejections under § 101 and § 112, first paragraph, which rejections should be withdrawn.

Claims 1-32 have been rejected under the judicially created doctrine of double patenting over claims 1-32 of United States Patent No. 6,686,347 which is the parent of the present application. To overcome this rejection, submitted herewith is a terminal disclaimer.

Applicants respectfully submit that the present case is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7898


Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Date: *November 18, 2004*